Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

FORGOTTEN HISTORY: Takeda pharma maintains outlook even as vyvanse generics hit sales | History Defined

Takeda Pharma-Photo by Veroniksha via Shutterstock

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

The company reported earnings per American Depositary Share (EPADS) of 52 cents, surpassing analyst expectations of 47 cents. However, in yen terms, earnings per share (EPS) experienced a 14.1% decline, or a 10% decrease when adjusted for constant currency, reaching 151 yen.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.